Zealand University Hospital, Department of Cardiology

The Department of Cardiology at Zealand University Hospital advances research in heart failure with preserved ejection fraction, systemic inflammation, primary prevention of atherosclerotic cardiovascular disease, and acute ischemic stroke, aiming to improve patient outcomes and reduce cardiovascular mortality.

• Heart failure with preserved ejection fraction and systemic inflammation
• Primary prevention of atherosclerotic cardiovascular disease
• Acute ischemic stroke therapeutic strategies
• Evaluation of novel anti‑inflammatory agents
• Assessment of lipid‑lowering RNA‑based therapy

The site’s two investigators coordinate eight ongoing trials, integrating clinical expertise with patient‑centered care.

Research at the center focuses on blood‑cancer subtypes such as Philadelphia chromosome‑positive B‑cell acute lymphoblastic leukemia and ABL‑class Ph‑like B‑ALL, exploring chemo‑immunotherapy backbones that combine targeted agents and immunotherapies to enhance survival.

• Treatment strategies for Philadelphia chromosome‑positive B‑ALL
• Therapeutic approaches for ABL‑class Ph‑like B‑ALL
• Integration of immunotherapy with tyrosine‑kinase inhibitors
• Safety and toxicity profiling of novel chemo‑immunotherapy
• Long‑term survival outcomes in children and young adults

Ongoing trials benefit from the department’s expertise in hematologic malignancies and close collaboration with national oncology networks.

The site conducts oncology studies targeting solid tumours, notably non‑small cell lung cancer with programmed death‑ligand 1 expression, to evaluate new checkpoint inhibitors and compare them with standard chemotherapy.

• PD‑L1 positive non‑small cell lung cancer
• Comparison of novel checkpoint inhibitor with chemotherapy
• Overall survival benefit assessment
• Biomarker exploration for treatment response
• Combination strategies with standard of care

These trials aim to expand therapeutic options for patients with advanced lung cancer and improve long‑term outcomes.

Studies address acute and chronic respiratory conditions, including COVID‑19, chronic obstructive pulmonary disease, and vaccine efficacy in older adults, to develop effective therapies and preventive measures.

• Hospitalized adults with acute respiratory infections
• Antiviral protease inhibitor for COVID‑19
• Long‑term efficacy of tozorakimab in COPD exacerbations
• Immunogenicity of high‑dose influenza vaccine in adults 50+
• Safety of novel therapeutic platforms for viral emergencies

The platform enables rapid activation of trials during respiratory viral outbreaks, supporting public health responses.

The research portfolio includes investigations of viral pathogens such as influenza and COVID‑19, focusing on antiviral agents, vaccine responses, and the interplay between viral infections and cardiovascular risk.

• Antiviral efficacy in hospitalized COVID‑19 patients
• Safety of new protease inhibitor therapies
• Vaccine immunogenicity in high‑risk populations
• Strategic platform for rapid trial activation during viral outbreaks
• Impact of viral infections on cardiovascular comorbidities

Collaborative efforts with infectious disease specialists enhance the translational impact of these studies.